BioCentury
ARTICLE | Company News

U of Birmingham spins out RA newco

May 14, 2018 11:06 PM UTC

University of Birmingham (Birmingham, U.K.) spun out newco Viatem Ltd. to develop rheumatoid arthritis therapies based on a peptide that plays a role in the recruitment of immune cells to inflamed tissues.

The newco will discover and develop compounds around the peptide inhibitor of trans-endothelial migration (PEPITEM), a key regulator of the adiponectin (ADIPOQ) pathway that modulates T cell migration from blood into tissues. A research group led by University of Birmingham Professor of Chronic Inflammation Ed Rainger discovered the ADIPOQ pathway and found that patients with RA had reduced serum PEPITEM levels compared with healthy controls. The group published the findings in Nature Medicine in 2015...

BCIQ Company Profiles

University of Birmingham

BCIQ Target Profiles

Adiponectin (ADIPOQ)